-
Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations
Tamar Plitt & Dmitriy Zamarin
Clinical Trail Outcomes: Clinical Investigation
-
Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations
Tamar Plitt & Dmitriy Zamarin
Clinical Trail Outcomes: Clinical Investigation
-
Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations
Tamar Plitt & Dmitriy Zamarin
Clinical Trail Outcomes: Clinical Investigation
-
Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations
Tamar Plitt & Dmitriy Zamarin
Clinical Trail Outcomes: Clinical Investigation
-
Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations
Tamar Plitt & Dmitriy Zamarin
Clinical Trail Outcomes: Clinical Investigation
-
Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations
Tamar Plitt & Dmitriy Zamarin
Clinical Trail Outcomes: Clinical Investigation
-
Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations
Tamar Plitt & Dmitriy Zamarin
Clinical Trail Outcomes: Clinical Investigation
-
Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations
Tamar Plitt & Dmitriy Zamarin
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Overview on clinical trials in Waldenstroms macroglobulinemia
Alessandra Tedeschi, Anna Maria Frustaci, Paola Picardi & Enrica Morra
Clinical Trail Outcomes: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 12
Acknowledgements: Clinical Investigation
-
Considerations in the design of clinical trials for relapsing multiple sclerosis
Richard Nicholas, Tim Friede
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for relapsing multiple sclerosis
Richard Nicholas, Tim Friede
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for relapsing multiple sclerosis
Richard Nicholas, Tim Friede
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for relapsing multiple sclerosis
Richard Nicholas, Tim Friede
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for relapsing multiple sclerosis
Richard Nicholas, Tim Friede
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for relapsing multiple sclerosis
Richard Nicholas, Tim Friede
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for relapsing multiple sclerosis
Richard Nicholas, Tim Friede
Clinical Trail Methodology: Clinical Investigation
-
Considerations in the design of clinical trials for relapsing multiple sclerosis
Richard Nicholas, Tim Friede
Clinical Trail Methodology: Clinical Investigation
-
IL-17 in systemic lupus erythematosus
Wu Qian, Antonio La Cava
Review: Clinical Trail Outcomes: Clinical Investigation
-
IL-17 in systemic lupus erythematosus
Wu Qian, Antonio La Cava
Review: Clinical Trail Outcomes: Clinical Investigation
-
IL-17 in systemic lupus erythematosus
Wu Qian, Antonio La Cava
Review: Clinical Trail Outcomes: Clinical Investigation
-
IL-17 in systemic lupus erythematosus
Wu Qian, Antonio La Cava
Review: Clinical Trail Outcomes: Clinical Investigation
-
IL-17 in systemic lupus erythematosus
Wu Qian, Antonio La Cava
Review: Clinical Trail Outcomes: Clinical Investigation
-
IL-17 in systemic lupus erythematosus
Wu Qian, Antonio La Cava
Review: Clinical Trail Outcomes: Clinical Investigation
-
IL-17 in systemic lupus erythematosus
Wu Qian, Antonio La Cava
Review: Clinical Trail Outcomes: Clinical Investigation
-
IL-17 in systemic lupus erythematosus
Wu Qian, Antonio La Cava
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Clinical trials in idiopathic pulmonary fibrosis: update and perspectives
Eva Baroke, Shyam Maharaj, Martin Kolb
Review Article: Clinical Investigation
-
Current conceptions of the etiology and risk factors for Alzheimer\\\'s disease and their possible implications on the design of dementia clinical trials
Ramit Ravona-Springer, Amos D Korczyn
Review Article: Clinical Investigation
-
Current conceptions of the etiology and risk factors for Alzheimer\\\'s disease and their possible implications on the design of dementia clinical trials
Ramit Ravona-Springer, Amos D Korczyn
Review Article: Clinical Investigation
-
Current conceptions of the etiology and risk factors for Alzheimer\\\'s disease and their possible implications on the design of dementia clinical trials
Ramit Ravona-Springer, Amos D Korczyn
Review Article: Clinical Investigation
-
Current conceptions of the etiology and risk factors for Alzheimer\\\'s disease and their possible implications on the design of dementia clinical trials
Ramit Ravona-Springer, Amos D Korczyn
Review Article: Clinical Investigation
-
Current conceptions of the etiology and risk factors for Alzheimer\\\'s disease and their possible implications on the design of dementia clinical trials
Ramit Ravona-Springer, Amos D Korczyn
Review Article: Clinical Investigation
-
Current conceptions of the etiology and risk factors for Alzheimer\\\'s disease and their possible implications on the design of dementia clinical trials
Ramit Ravona-Springer, Amos D Korczyn
Review Article: Clinical Investigation
-
Current conceptions of the etiology and risk factors for Alzheimer\\\'s disease and their possible implications on the design of dementia clinical trials
Ramit Ravona-Springer, Amos D Korczyn
Review Article: Clinical Investigation
-
Current conceptions of the etiology and risk factors for Alzheimer\\\'s disease and their possible implications on the design of dementia clinical trials
Ramit Ravona-Springer, Amos D Korczyn
Review Article: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation
-
Tweaking potential research participants to meet clinical trial eligibility criteria: ethical concerns and scientific implications
Blair Henry, Yulia Lin, Jeannie Callum
Editorial: Clinical Investigation